Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
about
Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studiesDiagnosis and treatment of latent infection with Mycobacterium tuberculosisIncidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosisMechanism of isoniazidāinduced hepatotoxicity: then and nowTreatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting.Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysisCurrent Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in KoreaAntitubercular therapy in patients with cirrhosis: challenges and optionsIntuitive weights of harm for therapeutic decision making in smear-negative pulmonary Tuberculosis: an interview study of physicians in India, Pakistan and Bangladesh.Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature reviewExpression Profile of Markers of Apoptosis, Injury and Oxidative Stress in Human Lung Epithelium Cells-A5449 Receiving Chronic Exposure of Potential Anti-Tubercular Drug-trans-Cyclohexane-1, 4-Diamine Derivative-"9u".Adverse reactions to first-line antituberculosis drugs.Tuberculosis and illicit drug use: review and update.Empirical use of antituberculosis drugs should not be equated to their inappropriate and indiscriminate use.Antituberculosis drug-induced hepatotoxicity in childrenRisk factors for idiosyncratic drug-induced liver injury.Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas.Tuberculosis in the AIDS eraDrug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients.Clinical and biochemical profile of tuberculosis in patients with liver cirrhosisSevere hepatic complications of antituberculous therapyHypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.Pharmacogenetics of isoniazid-induced hepatotoxicity.Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment.Successful living donor liver transplantation of fulminant liver failure due to isoniazid prophylaxisA double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury.Causality assessment in drug-induced hepatotoxicity.Successful diagnosis of hyperpyrexia induced by isoniazid in a child with suspected extra-pulmonary tuberculosis.Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.The pregnane X receptor in tuberculosis therapeutics.Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like culturesRisk factors for hepatotoxicity from antituberculosis drugs: a case-control study.Hepatoprotective Effect of Cissus quadrangularis Stem Extract Against Rifampicin-induced Hepatotoxicity in RatsHepatotoxicity caused by the combined action of isoniazid and rifampicin.Antituberculosis treatment-induced hepatotoxicity: role of predictive factors.NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapyAntituberculosis drug-induced hepatotoxicity: concise up-to-date review.Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment.Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.
P2860
Q21257211-D707566B-8B2E-4174-AB74-6922DFBE7C88Q27021614-CF839B93-9D5C-4A2A-A6E2-5DB2853777A3Q28207601-68D502AE-BD96-41C1-9EBE-342CD404A4AFQ29248263-79C7416B-FAFD-464A-889D-247746D88220Q30383012-E655561A-E49F-4EB3-B528-44FD3497BA8AQ33390898-890568D0-38BC-4834-93CE-4083B4A46202Q33532816-CCF5D85E-1469-4060-B198-E064D4FD5695Q33567352-0405B387-FB1B-440C-BAA3-C61AAFFB8ABCQ33626827-EB37F926-A1E7-42B9-92BB-E6285D369C57Q34021616-FC194674-4E87-4490-8A88-F4C4831A13D7Q34116293-D5D0183B-567A-4BB4-8C1E-4CE58BFB0E05Q34221391-30CA57C4-AE5F-4158-8177-FC7A43583258Q34497890-82683DEA-04DD-417F-8F29-766D9E7EE2DAQ34601143-E9EEB2D8-F94D-46CF-A694-706BE342B041Q35040353-829C77F8-72E2-478E-A65F-909CB11D5F7CQ35096954-020A59E3-36D7-420E-A330-2C7BB690E3B1Q35168108-5CDC9EEF-0E0C-48A1-9F2B-BD982EBFF9D3Q35336540-617A83DF-3E2B-4DD4-833C-8594A946C232Q35365963-29BC7E02-C707-45AE-BADD-219F890B3F77Q35534713-0B3F6A4E-A439-477F-B83B-7B8A0CA28A24Q35555629-86A59726-37AB-48CA-85D1-AC7C0994D059Q35649646-0661FC30-7CC7-4FD8-B84A-A3764327C3E8Q35657599-22F240C7-3EA8-4CB4-8ADF-0C88990EE5BBQ35669887-73BAA5D3-7CE3-436F-941C-7ECD714B5FC5Q35714933-0EE71129-9C6C-4EF3-94B4-0A4F4CC33F9EQ35779237-1FE54D52-6FAE-4DDA-B709-F55816B01091Q35786010-489E55B3-32CE-4F63-9526-69555D0D20D1Q35842573-3503808B-F3FD-42E1-B874-E212D0ECE297Q35871161-3A77C350-6CD3-4A37-8DC2-3E0197C8115EQ36115081-2D380B80-B7D5-408B-B9E2-FC316C93F2C0Q36451492-01C1EE0B-19CA-4E48-BAF3-0FFD9CE04D8AQ36484652-2D412B6F-7C1C-4197-A81C-9DE6C2A1C32EQ36512029-D67932DD-4A51-4EED-A721-DE52544EC24FQ36537247-06CE589C-8262-4BFB-AFB6-BD3BC519F710Q36538437-A3874837-9DE9-4960-B06E-B702A1B87E0BQ36680092-326A90E0-25E4-4814-84ED-EEA8823735F3Q36809405-D69682AB-9543-4101-A592-883D490F2F91Q36998032-529D010F-F4B9-44EF-8494-BDA7C17D948EQ37043444-D60EF855-8120-4F64-AF5E-45A1A7823028Q37211281-4B1E6984-6201-4989-A99B-CB1C6188BBDE
P2860
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
description
1991 nĆ® lÅ«n-bĆ»n
@nan
1991 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ„ÕæÖÕøÖÕ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
1991 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« ÖÕ„ÕæÖÕ¾Õ”ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
1991幓ć®č«ę
@ja
1991幓č«ę
@yue
1991幓č«ę
@zh-hant
1991幓č«ę
@zh-hk
1991幓č«ę
@zh-mo
1991幓č«ę
@zh-tw
1991幓č®ŗę
@wuu
name
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
@ast
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
@en
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
@nl
type
label
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
@ast
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
@en
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
@nl
prefLabel
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
@ast
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
@en
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
@nl
P2093
P356
P1433
P1476
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
@en
P2093
P304
P356
10.1378/CHEST.99.2.465
P407
P577
1991-02-01T00:00:00Z